Results 201 to 210 of about 1,569,657 (332)

Cardiac Arrhythmias

open access: yesJournal of the American College of Cardiology, 2006
openaire   +3 more sources

Heart failure in two male patients with late‐onset Fabry mutation (IVS4 + 919G > A)

open access: yes
ESC Heart Failure, Volume 12, Issue 2, Page 1508-1513, April 2025.
Xufei Yang   +3 more
wiley   +1 more source

Exercise limitations in amyloid cardiomyopathy assessed by cardiopulmonary exercise testing—A multicentre study

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1326-1335, April 2025.
Abstract Aims Amyloid cardiomyopathy is caused by the deposition of light chain (AL) or transthyretin amyloid (ATTR) fibrils, that leads to a restrictive cardiomyopathy, often resulting in heart failure (HF) with preserved or reduced ejection fraction.
Robin Willixhofer   +25 more
wiley   +1 more source

Psychological Interventions for Reducing Distress in Patients with Cardiac Arrhythmias. [PDF]

open access: yesCurr Cardiol Rep
Särnholm J   +4 more
europepmc   +1 more source

Cardiac arrhythmias

open access: yesJournal of the American College of Cardiology, 2004
openaire   +3 more sources

Cardiogenic shock mortality according to Aetiology in a Mediterranean cohort: Results from the Shock‐CAT study

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1336-1345, April 2025.
Abstract Aims Mortality in cardiogenic shock (CS) remains elevated, with the potential for CS causes to impact prognosis and risk stratification. The aim was to investigate in‐hospital prognosis and mortality in CS patients according to aetiology. We also assessed the prognostic accuracy of CardShock and IABP‐SHOCK II scores.
Cosme García‐García   +17 more
wiley   +1 more source

Correction: “Re-evaluation of variants of uncertain significance in patients with hereditary arrhythmogenic disorders”

open access: yesBMC Cardiovascular Disorders
Sarah Martin   +4 more
doaj   +1 more source

Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1358-1373, April 2025.
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen   +7 more
wiley   +1 more source

Macrolide Antibiotic Mediated Cardiac Arrhythmias: Emerging Concepts and Clinical Implications. [PDF]

open access: yesBiomedicines
Iqbal F   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy